Drug Profile

Research programme: antibody therapeutics - ABL Bio

Alternative Names: ABL101-108; TRIA001; TRIA002; TRIO2-01

Latest Information Update: 27 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ABL Bio
Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Checkpoint kinase inhibitors; Immunostimulants; Natural killer cell stimulants; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 May 2024 TRIGR and ABL Bio terminates the licence for Antibody therapeutics in May 2021
28 Jan 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in South Korea (Parenteral)
28 Jan 2023 No recent reports of development identified for preclinical development in Solid-tumours in South Korea (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com